Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related ...

Immunovant (NASDAQ:IMVT – Free Report) had its price objective decreased by Bank of America from $38.00 to $33.00 in a ...

Immunovant said on Wednesday its experimental treatment for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following ...

Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...